DOP2013000221A - INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA - Google Patents

INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA

Info

Publication number
DOP2013000221A
DOP2013000221A DO2013000221A DO2013000221A DOP2013000221A DO P2013000221 A DOP2013000221 A DO P2013000221A DO 2013000221 A DO2013000221 A DO 2013000221A DO 2013000221 A DO2013000221 A DO 2013000221A DO P2013000221 A DOP2013000221 A DO P2013000221A
Authority
DO
Dominican Republic
Prior art keywords
tropomiosine
pirimidine
pirrolo
inhibitors related
quinase
Prior art date
Application number
DO2013000221A
Other languages
English (en)
Inventor
Kiyoyuki Omoto
Thomas Ryckmans
Karl Richard Gibson
Paul Anthony Stupple
Mark David Andrews
Sharanjeet Kaur Bagal
Sarah Elizabeth Skerratt
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000221(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of DOP2013000221A publication Critical patent/DOP2013000221A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de Formula (I) y sus sales aceptables para uso farmacéutico donde los sustituyentes son como se describen en Ia presente, y su uso en medicina, en particular como antagonistas de Trk.
DO2013000221A 2011-04-05 2013-10-04 INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA DOP2013000221A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471758P 2011-04-05 2011-04-05

Publications (1)

Publication Number Publication Date
DOP2013000221A true DOP2013000221A (es) 2014-03-16

Family

ID=45937493

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000221A DOP2013000221A (es) 2011-04-05 2013-10-04 INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA

Country Status (32)

Country Link
US (2) US8846698B2 (es)
EP (1) EP2694509B1 (es)
JP (1) JP5595616B2 (es)
KR (1) KR20130133905A (es)
CN (1) CN103534257A (es)
AP (1) AP2013007159A0 (es)
AR (1) AR085852A1 (es)
AU (1) AU2012238369A1 (es)
BR (1) BR112013025792A2 (es)
CA (1) CA2832291C (es)
CL (1) CL2013002821A1 (es)
CO (1) CO6801740A2 (es)
CR (1) CR20130470A (es)
CU (1) CU20130129A7 (es)
DO (1) DOP2013000221A (es)
EA (1) EA201391239A1 (es)
EC (1) ECSP13013009A (es)
ES (1) ES2581848T3 (es)
GE (1) GEP20156417B (es)
GT (1) GT201300236A (es)
IL (1) IL228590A0 (es)
MA (1) MA35024B1 (es)
MX (1) MX2013011612A (es)
NI (1) NI201300103A (es)
PE (1) PE20141050A1 (es)
PH (1) PH12013502020A1 (es)
SG (1) SG193513A1 (es)
TN (1) TN2013000394A1 (es)
TW (1) TWI443101B (es)
UA (1) UA108926C2 (es)
UY (1) UY34004A (es)
WO (1) WO2012137089A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013259344A1 (en) * 2012-05-11 2014-11-13 Abbvie Inc. Nampt inhibitors
JP2015531393A (ja) * 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
WO2014053968A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
JP2015531394A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
JP2016169161A (ja) * 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
TWI663159B (zh) 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EP3080072A4 (en) 2013-12-12 2017-07-19 Kalyra Pharmaceuticals, inc. Bicyclic alkyl compounds and synthesis
EP3083602A1 (en) 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
EP3097095A1 (en) * 2014-01-24 2016-11-30 AbbVie Inc. Furo-3-carboxamide derivatives and methods of use
WO2015120136A1 (en) 2014-02-05 2015-08-13 VM Oncology LLC Compositions of compounds and uses thereof
CN113336653A (zh) 2014-03-07 2021-09-03 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
EP3140298A1 (en) * 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
CN103992319B (zh) * 2014-05-27 2015-09-16 天津市斯芬克司药物研发有限公司 一种吡啶羧酸类化合物的制备方法
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
CN106999451B (zh) 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
EP3233057A2 (en) 2014-12-18 2017-10-25 Genzyme Corporation Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
WO2016104434A1 (ja) * 2014-12-24 2016-06-30 武田薬品工業株式会社 複素環化合物
CN105837574B (zh) * 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3475280B1 (en) * 2016-06-23 2020-04-08 H. Hoffnabb-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
CN107011347B (zh) * 2017-04-18 2019-01-18 华东师范大学 一种4-氯-7H-吡咯并[2,3-d]嘧啶的合成方法
KR20200018440A (ko) 2017-05-15 2020-02-19 리커리엄 아이피 홀딩스, 엘엘씨 진통제 화합물
WO2018237134A1 (en) 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7279067B2 (ja) * 2018-03-28 2023-05-22 武田薬品工業株式会社 複素環化合物及びその用途
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
CN109053575A (zh) * 2018-08-24 2018-12-21 遵义医学院 3-环丙基-1-甲基-1h-吡唑-4-甲醛的制备工艺
WO2020084389A1 (en) * 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
CN113164508B (zh) 2018-12-19 2025-07-08 达萨玛治疗公司 与神经保护剂组合的sarm1抑制剂
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
US20230065740A1 (en) 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122141A1 (es) 2020-05-28 2022-08-17 Lilly Co Eli Inhibidor de trka
KR102889668B1 (ko) * 2020-11-03 2025-11-24 주식회사 엘지화학 작물보호제용 신규 화합물
EP4357347B1 (en) * 2021-06-21 2024-12-11 Henan Medinno Pharmaceutical Technology Co., Ltd. Trk kinase inhibitor compound and use thereof
TWI899933B (zh) 2023-04-06 2025-10-01 美商輝瑞大藥廠 經取代吲唑丙酸衍生化合物及其用途
WO2025007055A1 (en) * 2023-06-29 2025-01-02 Volastra Therapeutics, Inc. Aryl indol-3-yl ketone and aryl indazol-3-yl ketone inhibitors of kif18a
CN117720468A (zh) * 2023-12-15 2024-03-19 南开大学 一种用于筛选干预结直肠癌干细胞的靶点蛋白的活性探针
CN222533620U (zh) * 2024-05-11 2025-02-28 东莞市红象电子科技有限公司 按摩装置

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW438796B (en) 1996-05-15 2001-06-07 Hoffmann La Roche 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
GB0218168D0 (en) * 2002-08-06 2002-09-11 Astrazeneca Ab Compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
EP1706384A1 (en) 2004-01-07 2006-10-04 AstraZeneca AB Therapeutic agents i
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
EP1773836B1 (en) 2004-05-27 2012-09-05 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
CA2608733A1 (en) * 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
WO2007042545A1 (en) 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
RU2323058C1 (ru) 2006-07-12 2008-04-27 ООО Научно-внедренческий центр "Машины и оборудование для энергетики" Способ формирования наружной резьбы на концевом участке трубной заготовки
SI2076508T1 (sl) 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
WO2008080015A2 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
KR20100007956A (ko) 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8119637B2 (en) 2008-06-10 2012-02-21 Plexxikon Inc. Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症

Also Published As

Publication number Publication date
EA201391239A1 (ru) 2014-03-31
CR20130470A (es) 2013-10-16
AU2012238369A1 (en) 2013-10-03
CA2832291A1 (en) 2012-10-11
ES2581848T3 (es) 2016-09-07
NZ615557A (en) 2014-08-29
SG193513A1 (en) 2013-10-30
PE20141050A1 (es) 2014-08-30
CL2013002821A1 (es) 2014-02-21
TW201302757A (zh) 2013-01-16
WO2012137089A1 (en) 2012-10-11
CO6801740A2 (es) 2013-11-29
JP5595616B2 (ja) 2014-09-24
MX2013011612A (es) 2013-10-17
CU20130129A7 (es) 2014-01-29
AR085852A1 (es) 2013-10-30
EP2694509A1 (en) 2014-02-12
JP2014510131A (ja) 2014-04-24
TN2013000394A1 (fr) 2015-01-20
EP2694509B1 (en) 2016-05-18
UY34004A (es) 2012-11-30
US8846698B2 (en) 2014-09-30
CA2832291C (en) 2015-12-01
ECSP13013009A (es) 2013-12-31
US20140364415A1 (en) 2014-12-11
UA108926C2 (ru) 2015-06-25
AP2013007159A0 (en) 2013-10-31
US20120258950A1 (en) 2012-10-11
CN103534257A (zh) 2014-01-22
TWI443101B (zh) 2014-07-01
MA35024B1 (fr) 2014-04-03
IL228590A0 (en) 2013-12-31
GEP20156417B (en) 2015-12-25
PH12013502020A1 (en) 2018-04-11
KR20130133905A (ko) 2013-12-09
NI201300103A (es) 2014-02-12
BR112013025792A2 (pt) 2018-04-24
GT201300236A (es) 2015-08-04

Similar Documents

Publication Publication Date Title
ECSP13013009A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
DOP2014000203A (es) Compuestos de heterociclilo
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
UY33078A (es) Derivados de imidazoquinolina
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
MX2013011781A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
SV2010003472A (es) Compuestos de pirazol
MX2015008233A (es) Nuevos derivados de quinolona.
MX2015008052A (es) Inhibidores de prmt5 y sus usos.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
NI201300125A (es) Derivados de 2 - amino - 3 - ( imidazol - 2 - il ) - piridin - 4 - ona y su uso como inhibidores de cinasa del receptor vegf.
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
UY33240A (es) ?análogos de péptidos?.
CY1117356T1 (el) Νεα μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης της με ενα φαρμακευτικως αποδεκτο οξυ
CU20100158A7 (es) Pirrolo[2,3-d]pirimidinas y usos de las mismas como inhibidores de cinasa de tirosina
CU20100018A7 (es) Compuestos de pirazol
MX2013007952A (es) Antagonistas no competitivos de receptores nicotinicos.